Evidence map›Paper›PMID 41937716›Full record

ArticleHistology and histopathology2026

Characteristics of p53 and Smad4 immunohistochemistry in pancreatic ductal adenocarcinoma and validation by next-generation sequencing.

Ziqi Zhao, Juan Du, Wenyang Guo, Lingchao Liu, Congrong Liu, Limei Guo

Abstract read
PubMed Publisher
In one paragraph

Article in Histology and histopathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ziqi ZhaoDepartment of Pathology, Peking University Third Hospital, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.
Juan DuDepartment of Pathology, Peking University Third Hospital, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.
Wenyang GuoDepartment of Pathology, Peking University Third Hospital, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.
Lingchao LiuDepartment of Pathology, Peking University Third Hospital, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.
Congrong LiuDepartment of Pathology, Peking University Third Hospital, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.
Limei GuoDepartment of Pathology, Peking University Third Hospital, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China. guolimei@bjmu.edu.cn.

Funding

Noncommunicable Chronic Diseases-National Science and Technology Major Project of China 2025ZD0552400Noncommunicable Chronic Diseases-National Science and Technology Major Project of China 2025ZD0552411
6 · The paper itself

Abstract

backgroundMutations in four major driver genes -

methodsWe retrospectively enrolled 63 PDAC patients and systematically characterized the typical IHC expression patterns of p53 and Smad4. Targeted NGS was subsequently performed on all available tumor specimens, and the resulting mutational profiles were correlated with corresponding IHC findings. Diagnostic performance including sensitivity, specificity and accuracy of p53 IHC for predicting

resultsAmong the four canonical driver genes, co-occurring double- or triple-gene mutations were prevalent; within

conclusionOur study highlights the complementary diagnostic value of p53 and Smad4 IHC relative to molecular testing in PDAC, especially when tissue is limited, as commonly encountered in FNB specimens. The newly established Smad4 IHC classification system, which integrates an intermediate expression category into the conventional two-tier framework, demonstrates superior clinical utility and enhances predictive accuracy for

Indexed as

Biomarkers, TumorCarcinoma, Pancreatic DuctalPancreatic NeoplasmsSmad4 ProteinTumor Suppressor Protein p53AdultAgedAged, 80 and overFemaleHigh-Throughput Nucleotide SequencingHumansImmunohistochemistryMaleMiddle AgedMutationRetrospective StudiesBiomarkers, TumorSmad4 ProteinSMAD4 protein, humanTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID41937716

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.